NCT05307874 - Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor, Adult

Interventions

DRUG

ICT01

anti-BTN3A mAb IV Q3W

DRUG

Proleukin Injectable Product

1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

DRUG

Pembrolizumab injection

200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W

Trial Locations (5)

Institute Gustave Roussy, Paris

IUCT Oncopole Claudius Regaud, Toulouse

University Carl Gustav Carus, Dresden

Universitätsklinikum Wuerzburg, Würzburg

The Institute of Cancer Research, Sutton